MA25325A1 - Nouvelle gelule a dosage controle, la methode de production et la formulation des unites multiples qui la contiennent. - Google Patents

Nouvelle gelule a dosage controle, la methode de production et la formulation des unites multiples qui la contiennent.

Info

Publication number
MA25325A1
MA25325A1 MA26228A MA26228A MA25325A1 MA 25325 A1 MA25325 A1 MA 25325A1 MA 26228 A MA26228 A MA 26228A MA 26228 A MA26228 A MA 26228A MA 25325 A1 MA25325 A1 MA 25325A1
Authority
MA
Morocco
Prior art keywords
formulation
production method
same
multiple units
units containing
Prior art date
Application number
MA26228A
Other languages
English (en)
Inventor
Anders Ringberg
Torkel Gren
Martin Wikberg
Randy J Wald
Original Assignee
Pharmacia Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20413266&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA25325(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from PCT/SE1999/001463 external-priority patent/WO2000012069A1/fr
Application filed by Pharmacia Ab filed Critical Pharmacia Ab
Publication of MA25325A1 publication Critical patent/MA25325A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MA26228A 1998-11-11 2001-06-08 Nouvelle gelule a dosage controle, la methode de production et la formulation des unites multiples qui la contiennent. MA25325A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9803871A SE9803871D0 (sv) 1998-11-11 1998-11-11 Therapeutic method and formulation
PCT/SE1999/001463 WO2000012069A1 (fr) 1998-08-27 1999-08-26 Formulation de tolterodine therapeutique a liberation controlee

Publications (1)

Publication Number Publication Date
MA25325A1 true MA25325A1 (fr) 2001-12-31

Family

ID=20413266

Family Applications (1)

Application Number Title Priority Date Filing Date
MA26228A MA25325A1 (fr) 1998-11-11 2001-06-08 Nouvelle gelule a dosage controle, la methode de production et la formulation des unites multiples qui la contiennent.

Country Status (40)

Country Link
US (1) US6911217B1 (fr)
EP (1) EP1128819B1 (fr)
JP (1) JP3616011B2 (fr)
KR (1) KR100467384B1 (fr)
CN (1) CN1169522C (fr)
AP (1) AP1323A (fr)
AR (1) AR027815A1 (fr)
AT (1) ATE247458T1 (fr)
AU (1) AU762410B2 (fr)
BG (1) BG65149B1 (fr)
BR (1) BRPI9915142B8 (fr)
CA (1) CA2350061C (fr)
CZ (1) CZ299582B6 (fr)
DE (1) DE69910604T2 (fr)
DK (1) DK1128819T3 (fr)
EA (1) EA005074B1 (fr)
EE (1) EE05232B1 (fr)
ES (1) ES2204193T3 (fr)
GE (1) GEP20022833B (fr)
HK (1) HK1040917B (fr)
HR (1) HRP20010333B1 (fr)
HU (1) HU226582B1 (fr)
ID (1) ID30039A (fr)
IL (1) IL142809A0 (fr)
IS (1) IS2370B (fr)
MA (1) MA25325A1 (fr)
MY (1) MY122195A (fr)
NO (1) NO331399B1 (fr)
NZ (1) NZ511430A (fr)
OA (1) OA11673A (fr)
PL (1) PL195780B1 (fr)
PT (1) PT1128819E (fr)
RS (1) RS49891B (fr)
SE (1) SE9803871D0 (fr)
SI (1) SI1128819T1 (fr)
SK (1) SK284758B6 (fr)
TW (2) TWI267385B (fr)
UA (1) UA57165C2 (fr)
WO (1) WO2000027364A1 (fr)
ZA (1) ZA200103575B (fr)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998003067A1 (fr) * 1996-07-19 1998-01-29 Gunnar Aberg S(-)-tolterodine pour le traitement des troubles urinaires et gastro-intestinaux
US8563522B2 (en) 1997-07-08 2013-10-22 The Iams Company Method of maintaining and/or attenuating a decline in quality of life
EP0957073A1 (fr) 1998-05-12 1999-11-17 Schwarz Pharma Ag Dérivés de 3,3-diphénylpropylamines
SI1227806T1 (sl) * 1999-11-11 2005-12-31 Pfizer Health Ab Farmacevtska formulacija, ki vsebuje tolterodin in njena uporaba
AU2003265680A1 (en) * 2002-08-28 2004-03-19 Pharmacia Corporation Oral liquid tolterodine composition
US8168170B2 (en) 2002-10-03 2012-05-01 The Procter And Gamble Company Compositions having an inner core and at least three surrounding layers
ES2324712T5 (es) * 2003-01-22 2012-06-08 Pfizer Health Ab Dosis reducida de tolterodina para tratar trastornos urinarios
DE10315917A1 (de) * 2003-04-08 2004-11-18 Schwarz Pharma Ag Hochreine Basen von 3,3-Diphenylpropylaminmonoestern
EP2112920B1 (fr) 2003-06-26 2018-07-25 Intellipharmaceutics Corp. Capsules contenant un inhibiteur de la pompe a protons comprenant des unites secondaires differemment structurees permettant une liberation retardee de l'ingredient actif
PT2210605T (pt) 2003-11-04 2017-04-24 Tcd Royalty Sub Llc Formas de dosagem única diária de tróspio
WO2005046663A1 (fr) 2003-11-04 2005-05-26 Shire Laboratories, Inc. Composes d'ammonium quaternaire contenant des activateurs de la biodisponibilite
US20050158294A1 (en) 2003-12-19 2005-07-21 The Procter & Gamble Company Canine probiotic Bifidobacteria pseudolongum
US7785635B1 (en) 2003-12-19 2010-08-31 The Procter & Gamble Company Methods of use of probiotic lactobacilli for companion animals
US8877178B2 (en) 2003-12-19 2014-11-04 The Iams Company Methods of use of probiotic bifidobacteria for companion animals
US20050152884A1 (en) 2003-12-19 2005-07-14 The Procter & Gamble Company Canine probiotic Bifidobacteria globosum
US8894991B2 (en) 2003-12-19 2014-11-25 The Iams Company Canine probiotic Lactobacilli
US8394409B2 (en) * 2004-07-01 2013-03-12 Intellipharmaceutics Corp. Controlled extended drug release technology
US10624858B2 (en) 2004-08-23 2020-04-21 Intellipharmaceutics Corp Controlled release composition using transition coating, and method of preparing same
EP1629834A1 (fr) 2004-08-27 2006-03-01 KRKA, D.D., Novo Mesto Composition pharmaceutique de tolterodine avec liberation soutenue
US20060194987A1 (en) * 2005-01-10 2006-08-31 Kovacs Laszlo Z Process for preparing tolterodine tartrate
JP4938006B2 (ja) 2005-05-31 2012-05-23 ザ・アイムス・カンパニー ネコ科動物プロバイオティク・ビフィドバクテリア
AU2006253006B8 (en) 2005-05-31 2011-09-15 Alimentary Health Ltd Feline probiotic Lactobacilli
US10064828B1 (en) 2005-12-23 2018-09-04 Intellipharmaceutics Corp. Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
PT2997953T (pt) 2006-01-18 2019-02-04 Intec Pharma Ltd Dispositivo oe entrega para ingestão oral oe um agente
HUE056937T2 (hu) 2006-02-03 2022-04-28 Opko Renal Llc A D-vitamin elégtelenség és hiány kezelése 25-hidroxivitamin D2-vel és 25-hidroxivitamin D3-mal
KR100714058B1 (ko) * 2006-02-06 2007-05-02 한국유나이티드제약 주식회사 톨테로딘 엘-주석산염의 서방형 경구투여 조성물 및 이의 제조 방법
KR20080099334A (ko) * 2006-02-24 2008-11-12 테바 파마슈티컬 인더스트리즈 리미티드 메토프로롤 숙시네이트 서방정 및 이의 제조 방법
CA2645940A1 (fr) * 2006-03-21 2007-09-27 Teva Pharmaceutical Industries Ltd. Formule a liberation controlee de tolterodine
EP1839649A1 (fr) * 2006-03-31 2007-10-03 LEK Pharmaceuticals D.D. Formulations enrobées pour tolterodine
CA2648280C (fr) * 2006-04-03 2014-03-11 Isa Odidi Dispositif d'administration a liberation commandee comprenant un enrobage organosol
EP2015735A1 (fr) * 2006-04-21 2009-01-21 Synthon B.V. Perles de tolterodine
US10960077B2 (en) 2006-05-12 2021-03-30 Intellipharmaceutics Corp. Abuse and alcohol resistant drug composition
EP2026766A1 (fr) 2006-05-17 2009-02-25 Synthon B.V. Composition en comprimé pour la libération prolongée de la tamsulosine
PT2679228T (pt) 2006-06-21 2018-04-16 Opko Ireland Global Holdings Ltd Terapia utilizando um agente de repleção de vitamina d e um agente de substituição hormonal de vitamina d
JP2008007458A (ja) * 2006-06-29 2008-01-17 Freunt Ind Co Ltd レイヤリング用核粒子とその製造方法
EP2096923B1 (fr) 2006-11-27 2014-01-22 H. Lundbeck A/S Dérivés d'hétéroaryl-amides
EP2124966B1 (fr) 2007-02-01 2015-09-09 IAMS Europe B.V. Procédé pour réduire l'inflammation et le stress chez un mammifère en utilisant de glucose, d'avocat ou d'extraits d'avocat
PT2148684E (pt) 2007-04-25 2013-04-19 Cytochroma Inc Método de tratamento para a insuficiência e deficiência de vitamina d
KR101959952B1 (ko) 2007-04-25 2019-03-19 사이토크로마 인코포레이티드 비타민 ｄ 화합물과 밀랍성 담체를 포함하는 경구 조절성 방출 조성물
WO2008134523A1 (fr) 2007-04-25 2008-11-06 Proventiv Therapeutics, Llc Procédé sûr et efficace de traitement et de prévention de l'hyperparathyroïdie secondaire dans les maladies rénales chroniques
US20090017111A1 (en) * 2007-07-03 2009-01-15 Van Den Heuvel Dennie J M Tolterodine bead
US8486452B2 (en) * 2007-07-20 2013-07-16 Mylan Pharmaceuticals Inc. Stabilized tolterodine tartrate formulations
US8110226B2 (en) * 2007-07-20 2012-02-07 Mylan Pharmaceuticals Inc. Drug formulations having inert sealed cores
US8871275B2 (en) 2007-08-08 2014-10-28 Inventia Healthcare Private Limited Extended release compositions comprising tolterodine
CN101801350A (zh) 2007-08-13 2010-08-11 阿巴斯迪特宁医药有限公司 抗滥用药物、使用方法和制备方法
US20090192228A1 (en) * 2008-01-28 2009-07-30 Actavis Group Ptc Ehf Controlled-Release Tolterodine Compositions and Methods
US20090214665A1 (en) * 2008-02-26 2009-08-27 Lai Felix S Controlled Release Muscarinic Receptor Antagonist Formulation
CA2629099A1 (fr) * 2008-04-01 2009-10-01 Pharmascience Inc. Nouvelles formulations pharmaceutiques orales a liberation controlee
WO2009124210A1 (fr) 2008-04-02 2009-10-08 Cytochroma Inc. Procédés, compositions, utilisations, et kits utiles pour la carence en vitamine d et des troubles associés
WO2009140557A2 (fr) * 2008-05-14 2009-11-19 Capricorn Pharma, Inc. Formulations de toltérodine à libération modifiée
US9771199B2 (en) 2008-07-07 2017-09-26 Mars, Incorporated Probiotic supplement, process for making, and packaging
US8465770B2 (en) 2008-12-24 2013-06-18 Synthon Bv Low dose controlled release tablet
US10104903B2 (en) 2009-07-31 2018-10-23 Mars, Incorporated Animal food and its appearance
WO2011013082A1 (fr) * 2009-07-31 2011-02-03 Ranbaxy Laboratories Limited Compositions pharmaceutiques à unités multiples multi-couches
WO2011061616A2 (fr) 2009-11-23 2011-05-26 Micro Labs Limited Compositions à libération prolongée contenant de la toltérodine et procédé de préparation de celles-ci
WO2011095388A1 (fr) 2010-02-04 2011-08-11 Synthon Bv Microgranule de toltérodine
US11672809B2 (en) 2010-03-29 2023-06-13 Eirgen Pharma Ltd. Methods and compositions for reducing parathyroid levels
RU2566269C2 (ru) 2010-03-29 2015-10-20 Ферринг Б.В. Быстрорастворимая фармацевтическая композиция
JO3112B1 (ar) 2010-03-29 2017-09-20 Ferring Bv تركيبة دوائية سريعة التحلل
CA2796877A1 (fr) 2010-04-30 2011-11-03 Merck Sharp & Dohme Corp. Nouveaux agonistes du recepteur beta 3 adrenergique
US20120040008A1 (en) * 2010-08-11 2012-02-16 Ashish Chatterji Pharmaceutical compositions of metabotropic glutamate 5 receptor (mglu5) antagonists
WO2012154770A1 (fr) 2011-05-10 2012-11-15 Theravida, Inc. Associations de toltérodine et de stimulants salivaires pour traiter une vessie hyperactive
GR1007628B (el) 2011-07-27 2012-06-29 Φαρματεν Αβεε, Φαρμακευτικο σκευασμα περιεχον εναν αντιμουσκαρινικο παραγοντα και μεθοδος για την παρασκευη αυτου
KR20140061438A (ko) 2011-09-16 2014-05-21 훼링 비.브이. 속용성 약학 조성물
WO2013047795A1 (fr) * 2011-09-30 2013-04-04 アステラス製薬株式会社 Composition pharmaceutique granulaire
NZ702967A (en) 2012-07-12 2017-07-28 Ferring Bv Diclofenac formulations
KR20150083841A (ko) * 2012-09-20 2015-07-20 오에이치알 파마, 엘엘씨. 치료제의 서방을 위한 다층 생분해성 미세입자
TW201422254A (zh) 2012-11-21 2014-06-16 Ferring Bv 用於速釋及延釋的組成物
US20150306170A1 (en) * 2012-11-21 2015-10-29 Ferring B.V. Composition for immediate and extended release
HUE050303T2 (hu) * 2013-03-13 2020-11-30 Intervet Int Bv Stabil bioaktív szubsztanciák és eljárások elõállítására
KR101847947B1 (ko) 2013-03-15 2018-05-28 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 안정화되고 변형된 비타민 ｄ 방출 제형
US20140275038A1 (en) 2013-03-15 2014-09-18 Inspirion Delivery Technologies, Llc Abuse deterrent compositions and methods of use
AU2014246617A1 (en) 2013-12-23 2015-07-09 Sun Pharmaceutical Industries Limited Multi-layered, multiple unit pharmaceutical compositions
AU2015298858A1 (en) 2014-08-07 2017-03-02 Opko Ireland Global Holdings Ltd. Adjunctive therapy with 25-hydroxyvitamin D
US10729685B2 (en) 2014-09-15 2020-08-04 Ohemo Life Sciences Inc. Orally administrable compositions and methods of deterring abuse by intranasal administration
CA2936746C (fr) * 2014-10-31 2017-06-27 Purdue Pharma Methodes et compositions destinees au traitement du trouble de deficit d'attention
US20190083628A1 (en) * 2016-02-23 2019-03-21 Nipro Corporation Pharmaceutical composition particles and orally disintegrating preparation including the same
CA3018019A1 (fr) 2016-03-28 2017-10-26 Opko Ireland Global Holdings, Limited Procedes de traitement par la vitamine d

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1144911B (it) * 1981-03-19 1986-10-29 Pharmatec Spa Composizione farmaceutica a rilascio controllato contenente ibuprofen
JPH07107450A (ja) 1993-10-08 1995-04-21 Hitachi Ltd 情報通信装置
JP3453186B2 (ja) 1994-04-14 2003-10-06 共和薬品工業株式会社 徐放性マイクロカプセルおよびその製造方法
SE9402422D0 (sv) * 1994-07-08 1994-07-08 Astra Ab New beads for controlled release and a pharmaceutical preparation containing the same
US5645858A (en) * 1994-10-06 1997-07-08 Ortho Pharmaceutical Corporation Multilayered controlled release pharmaceutical dosage form
US5567441A (en) * 1995-03-24 1996-10-22 Andrx Pharmaceuticals Inc. Diltiazem controlled release formulation
WO1998003067A1 (fr) 1996-07-19 1998-01-29 Gunnar Aberg S(-)-tolterodine pour le traitement des troubles urinaires et gastro-intestinaux
US6312728B1 (en) * 1998-07-07 2001-11-06 Cascade Development, Inc. Sustained release pharmaceutical preparation

Also Published As

Publication number Publication date
EP1128819B1 (fr) 2003-08-20
BRPI9915142B8 (pt) 2021-05-25
SE9803871D0 (sv) 1998-11-11
SI1128819T1 (en) 2003-12-31
TWI267385B (en) 2006-12-01
DK1128819T3 (da) 2003-12-01
SK6252001A3 (en) 2002-01-07
HU226582B1 (en) 2009-04-28
DE69910604T2 (de) 2004-06-24
KR100467384B1 (ko) 2005-01-24
IL142809A0 (en) 2002-03-10
GEP20022833B (en) 2002-11-25
KR20010075695A (ko) 2001-08-09
WO2000027364A1 (fr) 2000-05-18
RS49891B (sr) 2008-08-07
ZA200103575B (en) 2002-05-03
CZ299582B6 (cs) 2008-09-10
DE69910604D1 (de) 2003-09-25
CA2350061C (fr) 2005-05-17
AU1436600A (en) 2000-05-29
CA2350061A1 (fr) 2000-05-18
TWI222879B (en) 2004-11-01
ATE247458T1 (de) 2003-09-15
NO331399B1 (no) 2011-12-19
JP2003517446A (ja) 2003-05-27
US6911217B1 (en) 2005-06-28
AP2001002166A0 (en) 2001-06-30
HK1040917A1 (en) 2002-06-28
EA005074B1 (ru) 2004-10-28
EP1128819A1 (fr) 2001-09-05
HUP0105038A3 (en) 2006-07-28
PL195780B1 (pl) 2007-10-31
SK284758B6 (sk) 2005-11-03
BRPI9915142B1 (pt) 2015-08-25
NO20012314D0 (no) 2001-05-10
HK1040917B (zh) 2005-05-27
HUP0105038A2 (en) 2002-06-29
BR9915142A (pt) 2001-08-07
OA11673A (en) 2005-01-12
CN1326339A (zh) 2001-12-12
ID30039A (id) 2001-11-01
EE05232B1 (et) 2009-12-15
ES2204193T3 (es) 2004-04-16
AR027815A1 (es) 2003-04-16
AU762410B2 (en) 2003-06-26
BG105582A (en) 2001-12-29
AP1323A (en) 2004-11-05
BG65149B1 (bg) 2007-04-30
YU33101A (sh) 2003-10-31
CZ20011627A3 (cs) 2001-10-17
IS5936A (is) 2001-05-09
CN1169522C (zh) 2004-10-06
IS2370B (is) 2008-06-15
UA57165C2 (uk) 2003-06-16
EA200100538A1 (ru) 2001-10-22
HRP20010333A2 (en) 2003-04-30
EE200100254A (et) 2002-12-16
HRP20010333B1 (en) 2004-10-31
MY122195A (en) 2006-03-31
PL348612A1 (en) 2002-06-03
PT1128819E (pt) 2003-12-31
NZ511430A (en) 2003-05-30
NO20012314L (no) 2001-07-09
JP3616011B2 (ja) 2005-02-02

Similar Documents

Publication Publication Date Title
MA25325A1 (fr) Nouvelle gelule a dosage controle, la methode de production et la formulation des unites multiples qui la contiennent.
NO973922D0 (no) Nye taxoider, deres fremstilling og farmasöytiske preparater inneholdende forbindelsene
MXPA03007712A (es) Sales farmaceuticas.
EE9700044A (et) Heteroarüüloksasolidinoonid, nende valmistamismeetod, kasutamine ravimite valmistamiseks ja nimetatud ühendeid sisaldavad ravimid.
DE69102531D1 (de) Mikrokapseln, Verkapselungsverfahren und Methode zur Anwendung derselben.
FI925615A0 (fi) Stabiliserade farmaceutiska kompositioner, som innehaoller en hmg-coa-reduktas-inhibitorfoerening
ZA965294B (en) Substituted 4-phenylaminothiazoles, their process of preparation and the pharmaceutical compositions containing them.
PL345863A1 (en) Benzocycloheptenes, method for the production thereof, pharmaceutical preparations containing these compounds, and their use for producing medicaments
HUP9800273A3 (en) Benzothiazine dioxides as endothelin antagonists, process for their production and pharmaceutical compositions containing the same
ZA983792B (en) New cysteine derivatives, processes for their production, and pharmaceuticals containing them.
WO2001058875A3 (fr) Derives substitues d'acide 1,2,3,4-tetrahydroquinoline-2-carboxylique
NO880473L (no) Fremgangsmaate til fremstilling av substituerte 3,4-dihydro-2h-benzopyraner og deres anvendelse som legemiddel.
NO883465D0 (no) Fremgangsmaate og mellomprodukter for fremstilling av 1-fenyl-3-(1-piperazinyl)-1h-indazoler, og anvendelse derav som medikamenter.
NO306156B1 (no) Substituerte benzyloksykarbonylguanidiner, deres anvendelse til fremstilling av medikament eller diagnostikum sÕvel som legemidler inneholdende disse
HUP9901376A3 (en) 1-methylcarbapenem derivatives, their use, production thereof and medicaments containing the same
ZA988711B (en) New tetracycles, process for their production and pharmaceutical preparations containing these compounds.
DE3481057D1 (de) 2-sulfamoylbenzo(b)thiophen-derivate, ihre herstellung und pharmazeutische zubereitung zur behandlung von erhoehtem augeninnendruck.
NO904576D0 (no) Aminopyridinylaminofenol og beslektede forbindelser, mellomprodukter, fremgangsmaate for deres fremstilling og anvendelse som medikamenter.
HUP9802731A3 (en) Vitamin d analogues, use thereof, medicaments containing them, their production
ATE125541T1 (de) Reine kristalline form von rifapentin.
IT8419657A0 (it) Farmaci contenenti muzolimin, loro impiego e procedimenti per la loro produzione.
NO306468B1 (no) Nye fosfolipid-derivater, deres fremstilling, legemiddel inneholdende derivatene og derivatenes anvendelse
NO894516D0 (no) Fremgangsmaate for fremstilling av 1-aminoalkyl-3-oksosubstituert-4-aryl-1,3,4,5-tetrahydro-2h-1,3-benzodiazepin-2-on, og deres anvendelse som medikamenter.
EE05184B1 (et) Kaloporosiidi derivaadid, nende valmistamine ja kasutamine ravimina, neid sisaldavad ravimid ning mikroorganismi Gloeoporus dichrous (Fr.:Fr.) tvi ST001714 (DSM 13784)
NO20035642D0 (no) Fremgangsmåte for fremstilling av derivater av 1,5-diaryl-3- trifluormetyl-delta2-pyrazoliner som er racemisk og enantiomerisk rene